Clinical pharmacology in adolescent transgender medicine (Q29809)

From lgbtDB
Revision as of 21:31, 7 November 2024 by Superraptor (talk | contribs) (‎Added [en] label: Clinical pharmacology in adolescent transgender medicine)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
No description defined
  • Clinical pharmacology in adolescent transgender medicine.
Language Label Description Also known as
English
Clinical pharmacology in adolescent transgender medicine
No description defined
  • Clinical pharmacology in adolescent transgender medicine.

Statements

Clinical pharmacology in adolescent transgender medicine. (English)
1 reference
Adolescent transgender medicine is a growing clinical field. (English)
© 2024 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
1 reference
Gender-affirming medications for transgender youth may include gonadotropin-releasing hormone (GnRH) agonists, gender-affirming hormones or both. (English)
© 2024 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
1 reference
To evaluate the potential effects of GnRH agonists (puberty suppression) on pharmacokinetic processes for transgender youth, we searched PubMed from inception to May 2024 for publications on the effects of GnRH agonists on drug absorption, distribution, metabolism or excretion for transgender adolescents or effects on hormones (including gonadotropins, adrenal androgens, sex steroids) that [...] (English)
© 2024 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
1 reference
No publications discussed the effects of GnRH agonist treatment on pharmacokinetic processes for adolescent transgender people. (English)
© 2024 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
1 reference
Sixteen publications observed marked decreases in gonadotropins and sex steroids for both adolescent transgender men and adolescent transgender women and slight effects on adrenal androgens. (English)
© 2024 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
1 reference
During GnRH agonist treatment, changes in body composition and body shape were greater for adolescent transgender people than for cisgender adolescent people. (English)
© 2024 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
1 reference
Further research is needed to better understand the effects of GnRH agonists on drug metabolism and other pharmacokinetic processes for transgender adolescents receiving GnRH agonists and other gender-affirming medications. (English)
© 2024 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
1 reference
October 2024
1 reference
October 2024
1 reference
90
1 reference
10
1 reference
2387-2397
1 reference
2387
1 reference
2397
1 reference